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Abstract: Smart nano–copolymeric matrices have been employed to load and release anti tuberculosis (anti –
TB) drugs combinated complexes of Ethambutol (EMB), Isoniazid (INH), Rifampicin (RMP) and Pyrazinamide 
(PZA). Copolymeric nanocarriers were synthesized using a microemulsion polymerization method previously 
reported. These nanocarriers can show selective swelling–collapse response under changes in local environments 
such  a  temperature,  pH,  solvent  composition  and  electrical  stimuli.  The  employ  of  these  kinds  of  systems 
permits a controlled and selective delivery and release on specific human tissues. High Performance Liquid 
Chromatography technique was used to allow the detection of combinated mixtures of different active principles 
of anti–TB drugs using an acetonitrile mobile phase at 0.5 mL/min of flow rate whit a Spherisorb ODS2, C18 
column. The results obtained suggest that the employ of smart nanohydrogels is a novel method in several 
tuberculosis therapies.   
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Introduction 
 
During the past decade the tuberculosis disease has generated a great worldwide focus of 
alarm  but  particularly in places  where the mortality rate caused by this  disease is  highly 
worrying
1.  Tuberculosis  (TB)  is  a  chronic  bacterial  infection  caused  by  Mycobacterium 
tuberculosis histologically characterized by the formation of granules. Typically, the disease 
is found in the lungs, but can affect almost any organ in the human body. TB is the most 
common cause of death from an infectious agent worldwide in adults
2. The discontinuation in 
the application of anti–TB drugs has several implications. Actually the treatment of this kind 
of diseases takes a long time to ensure that the infectious agent is eradicated from the host
3. 
Isoniazid  (INH)  is  the  most  powerful  mycobactericidal  drug  available  that  ensures  early MedJChem, 2011, 2(1),  A. Arredondo–Peñaranda
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sputum conversion and helps in decreasing the transmission of TB
4. Rifampicin (RMP) is a 
mycobactericidal with sterilizing activities and is crucial for preventing relapses. There are 
also another two drugs capable to be used to combat this disease: the Ethambutol (EMB) and 
Pyracinamide (PZA) 
5.  
Thus, Isoniazid and Rifampicin are keystone drugs in the management of TB
6. Otherwise, 
the particularly hepatoxicity, risk factors, morbidity and mortality from INH as well as the 
adverse reactions to RMP and EMB are well documented in literature
7–12. The adverse effects 
of these drugs can be decreased when they are used in a combinated way
13. One of the most 
versatile  methods,  not  used  enough,  to  administrate  this  kind  of  drugs  is  the  employ  of 
nanoparticles as drug carriers
14.  
The  synthesis  of  these  vehicles  includes  the  use  of  very  complex  methods  with  high 
precision and accuracy
15. Smart nanoparticles can act in a selective manner when they are 
functionalized through chemical procedures
16.  Smart polymers are macromolecules capable 
of  undergoing  rapid,  reversible  phase  transitions  from  a  hydrophilic  to  a  hydrophobic 
microstructure when triggered by small changes  in  their immediate environment, such  as 
slight variations in temperature, pH or ionic strength
17.  
Smart polymers are becoming increasingly more prevalent as scientists learn about the 
chemistry and triggers that induce conformational changes in polymer structures and devise 
ways to take advantage of, and control them
18. New polymeric materials are being chemically 
formulated that sense specific environmental changes in biological systems, and adjust in a 
predictable manner, making them useful tools for drug delivery or other metabolic control 
mechanisms
19.  
The versatility of particulate technologies enables tailoring of the nanoparticles based drug 
delivery systems with consideration of the target, desired pharmacokinetic profile, and route 
of administration
20. 
 
Results and Discussion 
 
Characterization of nanohydrogels  
By differential scanning calorimetry the glass transition temperature of the nanohidrogel 
was determined by the criterion of the midpoint and it was 98.2°C value which agrees with 
previous  reports
21  for  the  copolymer  of  NIPA–2AAECM–NPAM.  The  nuclear  magnetic 
resonance (¹H NMR) shows that the skeleton of the copolymer contains segments of NIPA, 
NPAM and 2AAECM and the calculated composition in weight was of 93.4% NIPA, 3.73% 
NPAM and 2.83% 2AAECM, values which are very close to added to the reactor (90% NIPA, 
5% NPAM and 5% 2AAECM). Figure 1 shows the ¹H NMR spectrum of a nanohydrogel.  
The FTIR spectrum of the nanohydrogels (Figure 2) confirmed the presence of major 
functional groups of the monomers (NIPA, 2AAECM and NPAM) in the skeleton of the 
copolymer. We observed bands to 2940 and 3298 cm 
–1 due to the vibration of the amide 
protons. NH and CH bonds of the aromatic ring of NPAM. The vibration of the NO2 group 
from NPAM appears near to 1350 cm
–1. There is also a confirmation of the NH group at 1560 
cm
–1 and a confirmation signal of NIPA and aromatic NPAM at 840 cm
–1.  
The particle size determined by QLS was 45.5 ± 11 nm measured in water milliQ grade, 
42.7 ± 9 nm measured in acetone and 57.4 ± 7 nm in buffer solution of pH 2. The average 
particle size determinated by scanning electron microscopy  (analysis  was  made by visual 
inspection and counting), was 54 nm. Figure 3 shows a scanning electron micrograph of the 
nanohydrogels. MedJChem, 2011, 2(1),  A. Arredondo–Peñaranda
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Figure 1. NMR 
1H spectrum of the nanohydrogels. 
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Figure 2. FTIR analysis of smart nanohydrogels (NIPA–co–NPAM–co–2AAECM). MedJChem, 2011, 2(1),  A. Arredondo–Peñaranda
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Figure 3. SEM photomicrography of the nanogels. 
 
 Release of ATD’s from drug-loaded nanohydrogels 
The monitoring of drug released from the nanohydrogels was made by high performance 
liquid chromatography (HPLC), following the EMB signal since it was the drug that produced 
a retention time of 3.5 min that differed clearly from those of the other three drugs (4.8, 7.2 
and 4.6 minutes for INH, RIF and PZA, respectively), and that it did not overlap with the 
peaks of the buffer that showed after four minutes.  
 
Table 1. Releasing measurements of ATD’s from smart nanocarriers by HPLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Releasing times  Retention time 
min 
Area 
µv·s 
Concentration 
ppm EMB 
0  0  0  0 
30  3.4  137659.7  0.5506388 
60  3.3  171578.5  0.686314 
90  3.4  295534.0  1.182136 
120  3.4  1014428.5  4.057714 
180  3.5  1821406.0  7.285624 
240  3.5  2215885.5  8.863542 
300  3.5  2078689.0  8.314756 
360  3.5  2122477.5  8.48991 
420  3.5  2230548.0  8.922192 
480  3.6  2520820.0  10.08328 
540  3.6  3011615.5  12.046462 
600  3.6  2945778.5  11.783114 
1800  3.7  3181426.0  12.725704 
3600  3.7  3134261.5  12.537046 MedJChem, 2011, 2(1),  A. Arredondo–Peñaranda
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In the study by UV–Vis spectrophotometry EMB located had the highest absorbance at 
197 nm, then the measurements on the HPLC detector were made at 200 nm. In Table 1 can 
be seen the follow–up EMB released at each time interval.  
The drug release media (buffer pH 2) intended to ensure that the degree of swelling of 
nanohydrogels were maximum; thus, facilitating the removal of the drug to the environment. 
 
Conclusion 
 
This  study  reports  for  the  first  time  the  use  of  nanohydrogels  from  a  copolymer  of 
acrylamide (NIPA–2AAECM–NPAM) sensitive to pH as a carrier for four first–line TB drugs 
in  a  simultaneously  way  and  their  subsequent  quantification  by  high  resolution  liquid 
chromatography. However, future studies would be required for the quantification of loading 
and release of the four drugs (INH, RIF, PZA and EMB) simultaneously did this study only 
for the EMB for ease of experiments and analysis. But even hypothesized that the other three 
drugs showed a comparable effectiveness, the EMB load and release given the simultaneous 
conditions  of  the  nanohydrogels  with  the  complex  of  the  four  antituberculosis  is  the 
preferment analytic procedure. 
It is important to note that although these release of drugs tests were supplemented with 
calculations of their kinetics; it is clear that there was an advance to verify the release of at 
least one of the four ATD’s and its quantification in function of time showed a trend of rapid 
growth  in  the  first  minutes  and  then  moderate  to  reach  the  first  hour  of  liberation. 
Furthermore, the size of nanoparticles used in this study, as it turned out, have an average of 
57.4 ± 7 nm at pH 2, favor their use as vehicles for oral drug delivery, taking into account that 
particles of less than 400 nm are taken intact from the intestine
23 . Even this particle size 
achieved by this novel technique of microemulsion synthesis, is very close to the required 
diameter (15–30 nm in the terminal vascular system) for these nanohydrogels can be injected 
via bloodstream without posing a problem of vascular obstruction
24, which is of great interest 
because it may release the drugs directly into the bloodstream throughout the body arrived in 
a very short time. These results suggest that the use of smart nanohydrogels could be an 
alternative to serve as vehicles for ATD’s complexes. 
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Experimental Section 
 
Materials  
Isoniazid  (INH)  ≥  99%,  rifampicin  (RIF)  ≥  97%,  Pyrazinamide  (PZA)    ≥    99%  and 
ethambutol  (EMB)  >  99%  were  obtained  from  Sigma  Chemicals  Co.  Acetonitrile  HPLC 
grade (LAB–SCAN Analytical Sciences), solution buffer pH 0.02 and pH 2.00 ± 7.00 ± 0.02 
(20°C)  ST  (Panreac),  concentrated  buffer  solution  pH  2.00  (Titrisol®,  Merck  Co.).  N–
Isopropylacrylamide  (NIPA)  (Aldrich  97%),  4–aminomethyl  pyridine  (4AMP)  (Aldrich 
98%), ethylenediamine (ED) (Aldrich 99%), acryloil chloride (Aldrich 96%), di–tert–butyl MedJChem, 2011, 2(1),  A. Arredondo–Peñaranda
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dicarbonate (BOC) (Aldrich 97%) and Dichloromethane (Aldrich 98%) were used without 
further  purification.  Chloroform  (for  analysis,  Merck  >  99%).  Diethyl  ether  (for  analysis 
99.7%),  ethyl  acetate  (99.8%)  and  potassium  nitrate  (>  99%)  were  provided  by  Panreac. 
Polyoxyethylene Sorbitol hexaoleate (Atlas G–1086) (99%) and sorbitan sesquiolate (Arlacel 
83) (98%) both obtained from Uniquema QC Laboratory, were used as received. Sodium 
chloride (NaCl) (Probus 98%), anhydrous sodium sulphate (Scharlau 99%), sodium disulfide 
(Merck  98%)  were  used  as  received.  The  monomers  N  (4–methyl  pyridine)  acrylamide 
(NPAM)  and  tert–butyl  2  acrylamidoethyl  carbamate  (2AAECM)  were  synthesized  by 
nucleophilic  substitution  reaction  from  BOC  and  modified  4AMP,  respectively.  The 
crosslinking agent N, N–methylene bisacrylamide (NMBA) (> 98%) was supplied by Fluka. 
The C18 column with pore size 5.0 μm and 4.6 mm·250 mm was provided by SunFire–Waters 
Co. (USA). This column was used with prior conditioning buffer solution pH 2.00. 
 
Methods  
Synthesis of smart nano–particles of NIPA–NPAM 2AAECM  
Copolymeric  nanoparticles  of  NIPA–2AAECM–NPAM  were  synthesized  using  a 
microemulsion  polymerization  process  using  a  reported  method
14,16.  The  microemulsion 
solution was introduced in a mechanical stirred reactor mantained at 25 ± 1°C and operated at 
131 rpm and nitrogen was bubbled to maintain an inert atmosphere during the reaction. The 
monomers  N–(4–methyl  pyridine)  acrylamide  (NPAM)  and  tert–butyl  2–acrylamidoethyl 
carbamate (2AAECM) are not commercial products; they were synthesized by a nucleophilic 
substitution reaction from the precursors, modified 4AMP and BOC, respectively. To obtain 
NPAM monomer, 4AMP reagent was previously prepared and reacted with acryloil chloride 
at – 5°C under vigorous stirring to produce a nucleophilic substitution by the amino functional 
group. The 2AAECM synthesis procedure involves several steps: the first was to obtain a di–
tert–butyl  dicarbonate  (BOC)  modified  by  reaction  with  ethylenediamine  at  –19°C  using 
dichloromethane as a reaction medium and when all the BOC was added the reaction was 
maintained  for  16  hours  at  25°C.  The  dichloromethane  was  evaporated  and  the  water 
insoluble diprotected amine formed as a secondary product was separated by adding water. 
Then,  the  diprotected  amine  was  separated  by  filtration  and  the  resulting  solution  was 
saturated with NaCl and extracted with ethyl acetate. The resulting solution was dried by 
adding anhydrous sodium sulphate and the product was obtained by rotoevaporation. This 
product was reacted with acryloil chloride to produce the monomer (2AAECM).  
 
Characterization of nanoparticles of NIPA–2AAECM–NPAM 
Differential scanning calorimetry (DSC). A TA Instruments calorimeter (DSC 2920) was used 
to measure the glass transition temperature (Tg) of the nanohydrogels. Thermal analysis for 
nanohydrogels of poly (NIPA–co–NPAM–co–2AAECM) was performed from 0 to 200°C at 
a  heating  rate  of  10°C/minute  under  nitrogen  flow  (100  mL/min).  The  criterion  of  the 
midpoint was used to assign the Tg. 
 
Nuclear Magnetic Resonance (NMR). Characterization was performed to obtain NMR proton 
spectrum (¹H) for nanohydrogels in deuterated water (D2O) as a solvent, an instrument Bruker 
ACE (250 MHz) was  employed at  20°C. The chemical  shifts (δ) were measured in  ppm 
relative to deuterated water (δ = 7.26).  
 MedJChem, 2011, 2(1),  A. Arredondo–Peñaranda
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Fourier  Transform  infrared  Spectrophotometry  (FTIR).  The  spectra  of  the  nanohydrogels 
were collected using attenuated total reflectance (ATR) with a Smart Orbit accessory attached 
to a spectrophotometer Fourier Transform Infrared FTIR (Nicolet 6700). All spectra were 
obtained from an average of 100 scans with 4 cm
–1 of resolution. 
 
Quasielastic Light Scattering (QLS). Approximately 5 mg samples of nanohydrogels were 
dispersed in 10 mL of water and acetone, and kept under constant agitation for at least five 
days. Then was measured the particle size. The measurements were made at an angle of 90°, 
the detection time for each sample was 2 minutes and the measurements were repeated at least 
five times and the average of the values was reported.  
 
Scanning Electron Microscopy (SEM). SEM micrographs were taken using a JEOL electron 
microscope at 10.0 kV JSM7000F equipped with a field emission microscope (FEM). For 
these experiments a layer of gold was deposited on the specimen. The spherical shape of the 
nanoparticles synthesized was confirmed by these measures. 
 
Loading the NIPA–2AAECM nanoparticles with anti TB drugs complex  
First, TB drugs or ATDS (Anti tubercular Drugs) (INH, RIF, PZA and EMB) were dissolved 
in 10 mL of a buffer solution of pH 2, at a concentration of 10,000 ppm and maintained under 
constant agitation for five hours. The concentration of each drug was in the proportion that 
each of the 900 mg tablets used in tuberculosis treatment
 24,25 (8.33, 16.67, 44.44 and 30.56% 
wt. for INH, RIF, PZA and EMB, respectively).  NIPA–co–2AAECM–co– NPAM hydrogels 
(approx. 1.5 g) were suspended in 50 mL of a buffer solution of pH 2 and maintained under 
constant agitation for five hours. Then the solution of the drug compounds was added drop by 
drop to the suspension of nanohydrogels under continuous stirring. This suspension was left 
under constant agitation for about 15 hours, then a few drops of NaOH aqueous solution (50% 
w/w) were added to reach pH 7 ± 0.2 and the nano hydrogels suspension was left to sediment 
for four hours and the supernatant was separated by centrifugation at 4500 for 10 minutes and 
stored for subsequent calculations. An aqueous buffer of pH 7 was added to the precipitate 
and centrifuged under the same conditions (4,500 rpm for 10 minutes). As in the previous step 
the resulting supernatant was stored. The precipitate (loaded nanohydrogels) obtained at the 
end of the second centrifugation was placed in a Petri dish and allowed to dry in an oven vent 
at 50°C for twenty–four hours to remove any residual solvent. Loaded nanohydrogels were 
stored in a glass jar and left it on the stove vent at 50°C. 
  
In–vitro release studies 
The release of the nanohydrogels loaded with ATD’s was conducted by adding 15 to 20 mg of 
loaded nanohydrogels in 10 mL of a buffer solution of pH 2 at 37 ± 1°C under continuous 
stirring. Time zero was taken when the loaded nanohydrogels were added to the experiment 
solution. Aliquots were taken at zero time, 30, 60, 90, 120, 180, 240, 300, 360, 420, 480, 540 
and 600 s, at 30 min and at 60 min. These aliquots were stored in plastic vials until HPLC 
injection.  
Quantification of EMB by HPLC. To determine the wavelength of maximum absorbance of 
EMB a scanning spectrophotometer UV–Vis (Cintra GBC model 303) was used to determine 
the wavelength of maximum absorbance of EMB, which was 197 nm. Then standards were 
prepared with concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 ppm of EMB in 
solutions with pH 2. Each standard was injected into the chromatograph separately using the MedJChem, 2011, 2(1),  A. Arredondo–Peñaranda
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same  elution  conditions:  carrier  flow  of  0.5  mL/min,  column  temperature  50°C  and  the 
detection wavelength was set at 200 nm. The mobile phase was acetonitrile (HPLC grade) in 
all cases. Table 1 shows the calibration values for the standards of EMB. In a similar way, 
quantification of the other drugs by HPLC was carried out. For calibration curves, peak area 
data of each standard (in microvolts·s) at  the corresponding concentration (in ppm) were 
taken.  Linear  regression  from  the  experimental  points  was  obtained,  as  well  as  the 
experimental equation. The release curves can be observed in Figures 4A and 4B.  
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Figure 4A. Release kinetics for EMB from smart nanocarriers. Area vs. time. 
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Figure 4B. Release kinetics for EMB from smart nanocarriers. Concentration vs. time. 
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